Dynasore: Precision Dynamin GTPase Inhibitor for Endocytosis and Vesicle Trafficking Research

Executive Summary: Dynasore (SKU: A1605), supplied by APExBIO, is a noncompetitive inhibitor of dynamin GTPase enzymes with an IC₅₀ of 15 µM, validated for reversible inhibition of endocytosis in mammalian cells (Macia 2006, https://doi.org/10.1016/j.cub.2006.03.020). It blocks dynamin1, dynamin2, and Drp1, interfering with vesicle scission and trafficking (APExBIO, https://www.apexbt.com/dynasore.html). Dynasore is insoluble in water/ethanol but dissolves in DMSO at ≥16.12 mg/mL, with optimal storage at –20°C. Its use has advanced mechanistic studies of endocytic pathways in both cancer and neurodegenerative disease models (Zheng 2024, https://doi.org/10.1126/sciadv.ado0016). It remains a benchmark tool for dissecting vesicle trafficking and signal transduction in biomedical research.

Biological Rationale

Dynamin GTPases are essential for membrane fission events in endocytosis and vesicular trafficking. They mediate GTP-dependent scission of membrane vesicles, critical for processes such as receptor-mediated endocytosis, synaptic vesicle recycling, and mitochondrial fission (Ferguson and De Camilli 2012, https://doi.org/10.1146/annurev-biochem-052810-093819). Aberrations in these pathways contribute to diseases including cancer and neurodegenerative disorders. Targeting dynamin-dependent endocytosis enables mechanistic dissection of cellular uptake, signal transduction, and pathogen-host interactions. Recent studies, such as Zheng et al. (2024), highlight the importance of vesicle trafficking in cancer-microbiome signaling, where bacterial extracellular vesicles modulate tumor colonization (https://doi.org/10.1126/sciadv.ado0016).

Mechanism of Action of Dynasore

Dynasore is a cell-permeable, noncompetitive inhibitor of the GTPase activities of dynamin1, dynamin2, and Drp1 (APExBIO product page). It binds to the GTPase domain, preventing GTP hydrolysis without directly competing with GTP binding (Macia 2006, doi). This action blocks the conformational changes required for vesicle scission. In cell-based assays, Dynasore rapidly (within 2–5 min) and reversibly inhibits transferrin uptake, a canonical marker of clathrin-mediated endocytosis (Macia 2006). The effect is maintained across multiple cell types, including HL-1 cardiomyocytes and neurons. In addition, Dynasore inhibits synaptic vesicle endocytosis, making it valuable for studies of neurotransmission (Newton et al. 2006, https://doi.org/10.1523/JNEUROSCI.3441-06.2006).

Evidence & Benchmarks

• Dynasore inhibits dynamin GTPase activity with an IC₅₀ of 15 µM in vitro (Macia 2006, doi).
• Reversible inhibition of transferrin uptake is observed in HeLa cells at 80 µM Dynasore within 2 min, with effect reversed upon washout (Macia 2006, doi).
• Dynasore blocks synaptic vesicle endocytosis in neuronal cultures without affecting exocytosis, confirming specificity (Newton 2006, doi).
• In cancer models, Dynasore enables quantification of endocytosis-dependent vesicle trafficking and signal transduction in vitro (internal review).
• Emerging studies implicate vesicle trafficking inhibitors like Dynasore in the study of tumor-microbiome interactions, e.g., Fusobacterium nucleatum vesicle adhesion in colorectal cancer (Zheng 2024, doi).

Applications, Limits & Misconceptions

Dynasore's rapid, reversible inhibition profile is widely used in:

• Dissecting dynamin-dependent endocytosis in cancer and neurodegenerative disease models (Dynasore overview; this article updates with mechanistic cancer-microbiome findings).
• Quantitative studies of vesicle trafficking and cell signaling, enabling time-resolved inhibition (workflow article; expanded here with recent benchmarks and solubility guidance).
• Functional studies in neuronal, epithelial, and cardiac cell systems.
• Investigating pathogen-host vesicle interactions, including bacterial extracellular vesicle uptake (Zheng 2024, doi).

Dynasore (SKU A1605) is often deployed for short-term inhibition protocols, making it suitable for kinetic studies where washout and reversibility are essential (see comparative usability analysis; this article clarifies protocol optimization).

Common Pitfalls or Misconceptions

• Dynasore is not effective against endocytosis pathways that are dynamin-independent (e.g., caveolin-independent uptake).
• It does not inhibit GTPases outside the dynamin/Drp1 family under standard conditions (Macia 2006).
• Dynasore is insoluble in water and ethanol; improper solvent choice will reduce efficacy—DMSO is required at ≥16.12 mg/mL (APExBIO).
• It is not suitable for in vivo systemic administration without additional pharmacokinetic studies.
• Long-term or repeated use may lead to off-target effects or cellular adaptation; always validate specificity in context.

Workflow Integration & Parameters

For optimal results, prepare stock solutions in DMSO (≥16.12 mg/mL), warming to 37°C or sonication if needed. Store aliquots at –20°C for several months. For cell-based assays, dilute Dynasore into culture medium to the desired working concentration (typically 10–80 µM), ensuring final DMSO content does not exceed 0.1–0.5% v/v. Rapid inhibition of dynamin-dependent endocytosis is achieved within 2–5 minutes; washout restores activity within 10–20 minutes. Always include proper controls for DMSO and confirm reversibility by transferrin uptake or equivalent assays. See Dynasore product technical details for protocol guidance. For advanced discussion contrasting Dynasore with alternative inhibitors and workflow optimization, see this comparative review; this article integrates microbiome and cancer signaling benchmarks.

Conclusion & Outlook

Dynasore remains a gold-standard, noncompetitive dynamin GTPase inhibitor, enabling precise, quantitative dissection of endocytic and vesicle trafficking pathways. Its use has expanded from cell biology into cancer and microbiome research, where it helps elucidate mechanisms of vesicle-mediated signaling and tumor colonization. As new studies reveal the complexity of vesicle trafficking in disease and host-microbe interactions, Dynasore's rapid, reversible inhibition profile will continue to be indispensable for both mechanistic and translational research.